Cicero Theodore J, Wong Gordon, Tian Yuhong, Lynskey Michael, Todorov Alexandre, Isenberg Keith
Department of Psychiatry, Washington University School of Medicine, Campus Box 8134, 660 S. Euclid Avenue, St. Louis, MO 63110, USA.
Pain. 2009 Jul;144(1-2):20-7. doi: 10.1016/j.pain.2009.01.026. Epub 2009 Apr 10.
We used a large medical insurance claims database to identify three groups: chronic opioid use (>180 therapeutic days, N=3726); acute opioid use (<10 therapeutic days, N=37,108); and a non-opioid group (N=337,366) who filed at least one insurance claim but none for opioids. Our results showed that although chronic opioid users represented only 0.65% of the total population, they filed 4.56% of all insurance claims, used 45% of all opioid analgesics and had much more physical and psychiatric co-morbidity than the acute opioid or non-opioid samples. Women were substantially over-represented (>63%) in the chronic pain group and used a much greater share of all medical services than males, especially as they grew older. Although our data suggest that chronic pain is optimally managed in a multidisciplinary patient- and gender-specific treatment plan, this was rarely the case with internists being the primary, and often only, physician seen. Moreover, our data suggest that opioids were often used for conditions in which they are generally not indicated (e.g. arthritis and headaches) or contraindicated by co-existing physical ailments (COPD). Finally, we conclude that adherence to the WHO analgesic ladder and other pain treatment guidelines was relatively infrequent: first, opioid extended release preparations which are ideally suited for chronic pain were used only in one in four patients; and, second, the selection of a weak (propoxyphene, codeine, and tramadol) or strong opioid (e.g. morphine and oxycodone) seemed to be driven by numerous factors not necessarily related to the intensity or duration of pain.
长期使用阿片类药物组(治疗天数>180天,N = 3726);急性使用阿片类药物组(治疗天数<10天,N = 37108);以及非阿片类药物组(N = 337366),该组人群至少提交了一份保险理赔申请,但没有阿片类药物相关的理赔申请。我们的结果表明,尽管长期使用阿片类药物的患者仅占总人口的0.65%,但他们提交了所有保险理赔申请的4.56%,使用了所有阿片类镇痛药的45%,并且与急性使用阿片类药物组或非阿片类药物组相比,有更多的身体和精神合并症。慢性疼痛组中女性占比过高(>63%),并且使用的所有医疗服务份额比男性大得多,尤其是随着年龄的增长。尽管我们的数据表明,慢性疼痛在多学科、针对患者和性别的治疗方案中能得到最佳管理,但实际情况很少如此,内科医生是主要的,而且往往是唯一会诊的医生。此外,我们的数据表明,阿片类药物经常被用于一般不适用(如关节炎和头痛)或因并存身体疾病(慢性阻塞性肺疾病)而禁忌使用的情况。最后,我们得出结论,遵循世界卫生组织镇痛阶梯和其他疼痛治疗指南的情况相对较少:首先,理想情况下适用于慢性疼痛的阿片类缓释制剂仅四分之一的患者使用;其次,弱阿片类药物(丙氧芬、可待因和曲马多)或强阿片类药物(如吗啡和羟考酮)的选择似乎受到许多不一定与疼痛强度或持续时间相关的因素驱动。